R
Renata Walewska
Researcher at Royal Bournemouth Hospital
Publications - 59
Citations - 2765
Renata Walewska is an academic researcher from Royal Bournemouth Hospital. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 24, co-authored 52 publications receiving 2075 citations. Previous affiliations of Renata Walewska include University of Leicester & Leicester Royal Infirmary.
Papers
More filters
Journal ArticleDOI
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Jeff P. Sharman,Miklos Egyed,Wojciech Jurczak,Alan P Skarbnik,Alan P Skarbnik,John M. Pagel,Ian W. Flinn,Manali Kamdar,Talha Munir,Renata Walewska,Gillian Corbett,Laura Fogliatto,Yair Herishanu,Versha Banerji,Steven Coutre,George A Follows,Patricia F. Walker,Karin Karlsson,Paolo Ghia,Ann Janssens,Florence Cymbalista,Jennifer A. Woyach,Gilles Salles,William G. Wierda,Raquel Izumi,Veerendra Munugalavadla,Priti Patel,Min Hui Wang,Sofia Wong,John C. Byrd +29 more
TL;DR: The primary endpoint was progression-free survival between the two combination-therapy groups, assessed by independent review committee.
Journal ArticleDOI
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Meike Vogler,Michael Butterworth,Aneela Majid,Renata Walewska,Xiao-Ming Sun,Martin J. S. Dyer,Gerald M. Cohen +6 more
TL;DR: The data indicate that after therapy with ABT-737-related inhibitors, resistant CLL cells might develop in lymph nodes in vivo and that treatment strategies targeting multiple BCL2 antiapoptotic members simultaneously may have synergistic activity.
Journal ArticleDOI
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Anthony R. Mato,Lindsey E. Roeker,Nicole Lamanna,John N. Allan,Lori A. Leslie,John M. Pagel,Krish Patel,Anders Österborg,Daniel Wojenski,Manali Kamdar,Scott F. Huntington,Matthew S. Davids,Jennifer R. Brown,Darko Antic,Ryan Jacobs,Inhye E. Ahn,Jeffrey Pu,Krista Isaac,Paul M. Barr,Chaitra S. Ujjani,Mark B. Geyer,Ellin Berman,Andrew D. Zelenetz,Nikita Malakhov,Richard R. Furman,Michael Koropsak,Neil Bailey,Lotta Hanson,Guilherme Fleury Perini,Shuo Ma,Christine E. Ryan,Adrian Wiestner,Craig A. Portell,Mazyar Shadman,Elise A. Chong,Danielle M. Brander,Suchitra Sundaram,Amanda N. Seddon,Erlene K. Seymour,Meera Patel,Nicolas Martinez-Calle,Talha Munir,Renata Walewska,Angus Broom,Harriet S. Walter,Dima El-Sharkawi,Helen Parry,Matthew R. Wilson,Piers E.M. Patten,Jose Angel Hernandez-Rivas,Fatima Miras,Noemi Fernandez Escalada,Paola Ghione,Chadi Nabhan,Sonia Lebowitz,Erica Bhavsar,Javier López-Jiménez,Daniel Naya,José A. García-Marco,Sigrid S. Skånland,Raul Cordoba,Toby A. Eyre +61 more
TL;DR: The data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death.
Journal ArticleDOI
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Takashi Akasaka,Theodore Balasas,Lisa J. Russell,Keiji Sugimoto,Aneela Majid,Renata Walewska,E. Loraine Karran,David Brown,Kelvin Cain,Lana Harder,Stefan Gesk,José I. Martín-Subero,Mark G. Atherton,Monika Brüggemann,María José Calasanz,Teresa Davies,Oskar A. Haas,Anne Hagemeijer,Helena Kempski,Michel Lessard,Debra M. Lillington,Sarah Moore,Florence Nguyen-Khac,Isabelle Radford-Weiss,Claudia Schoch,Stéphanie Struski,Polly Talley,Melanie J. Welham,Helen Worley,Jonathan C. Strefford,Christine J. Harrison,Reiner Siebert,Martin J. S. Dyer +32 more
TL;DR: The findings implicate the CEBP gene family as novel oncogenes in BCP-ALL, and suggest opposing functions of CEBP dysregulation in myeloid and lymphoid leukemogenesis.
Journal ArticleDOI
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson,Lijian Yu,Robert J. Glynn,Jacqueline C. Barrientos,Eric D. Jacobsen,Versha Banerji,Jeffrey A. Jones,Renata Walewska,Kerry J. Savage,Gregory F. Michaud,Javid Moslehi,Jennifer R. Brown +11 more
TL;DR: Ibrutinib use is associated with atrial fibrillation (AF), with an incidence of 5% to 6% after 18 months on therapy.